CA-BELKIN
25.6.2024 17:01:34 CEST | Business Wire | Press release
Belkin, a leading consumer electronics brand for 40 years, today announced the availability of the BoostCharge Pro Magnetic Power Bank, built with Qi2 wireless charging technology. It is available to order today in 5K and 10K options, and in five fresh new colors – cyber lime, sand, pink, blue, and gold.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240625730951/en/
Belkin BoostCharge Pro Magnetic Power Bank 5K in cyber lime, sand, pink, blue and gold color options. (Photo: Business Wire)
Unveiled earlier this year, Belkin’s Qi2 power bank lineup delivers up to 15W of fast charging power for iPhone 12 models and later, without the hassle of cables. They are engineered with an integrated kickstand for propping the phone up while streaming, reading or chatting, and work with magnetic and MagSafe cases up to 3mm thick. They are designed to fit perfectly on the back of iPhone without obstructing camera. “Power pass-through” allows for charging the power bank and attached devices in one simple action via USB-C port.
BoostCharge Pro Magnetic Power Bank 5K
- Fast charges iPhone 12 models and later up to 15W with Qi2 when battery pack is plugged in, and up to 7.5W when used as battery pack
- Provides up to 16 hours of additional battery life1
- Built with 1 x USB-C port to charge two devices simultaneously2
- Packaged with USB-C to USB-C cable to start charging right out of the box
- Available in black, cyber lime, sand, pink, and blue color options; gold available in European markets only
- $59.95 USD
BoostCharge Pro Magnetic Power Bank 10K
- Fast charges iPhone 12 models and later up to 15W with Qi2 (delivers 0-25% charge in 21 minutes3), or up to 20W with integrated USB-C cable
- Provides up to 35 hours of additional battery life4
- Built with 1 x USB-C port and integrated USB-C cable to charge three devices simultaneously5
- Available in black
- $99.95 USD
In line with Belkin’s commitment to build products more responsibly, the BoostCharge Pro Magnetic Power Bank offerings are made with a minimum of 72% post-consumer recycled materials (PCR) and packaged in 100% plastic-free packaging.
Media kit can be found HERE.
About Belkin
Belkin is a California-based accessories leader delivering award-winning power, protection, productivity, connectivity, and audio products over the last 40 years. Designed and engineered in Southern California and sold in more than 100 countries around the world, Belkin has maintained its steadfast focus on research and development, community, education, sustainability and most importantly, the people it serves. From our humble beginnings in a Southern California garage in 1983, Belkin has become a diverse, global technology company. We remain forever inspired by the planet we live on, and the connection between people and technology.
___________
1 Maximum additional video playback hours calculated by comparing the mAh capacity of this power bank with the maximum video playback hours achievable by the iPhone 15 under normal conditions. Actual results will vary depending on differing factors for individual users.
2 When one device is charging: 7.5W wireless or USB-C 12W max output. When two devices are charging: 5W wireless + 5W max USB-C
3 Based on internal tests using iPhone 15; results may vary depending on various conditions.
4 Contains a 10,000 mAh internal battery. Amount of discharge to user’s device is less and may vary depending on various conditions. Maximum additional video playback hours calculated by comparing the capacity of the internal battery of this power bank with the maximum video playback hours achievable by the iPhone 15 under normal conditions. Actual results will vary depending on conditions and use.
5 When one device is charging: 15W wireless, or USB-C 20W max output. When two devices charging: 7.5W wireless + 10W max USB-C. When three devices charging: 15W max shared
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240625730951/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Duco Launches the First Agentic Operations Platform for Financial Services27.5.2026 09:20:00 CEST | Press release
Duco, today launched the first agentic Operations platform for financial services. Built on the engine that already processes 20 billion transactions every month for more than 200 clients, including seven of the top 20 banks and ten of the top 20 asset managers, the platform brings together everything firms need to run post-trade Operations alongside autonomous agents, safely and at scale. The launch establishes a breakthrough the industry has been waiting for. A tool surface, purpose-built for agents. Duco has unbundled its platform into a new alternative agent layer that reconfigures its platform into hundreds of discrete capabilities servicing post trade. Model Context Protocol (MCP) gives capabilities covering reconciliation, data preparation, data access, audit trails, exception management, document creation and more. For the first time, agents have a verified, deterministic toolset built specifically for post-trade. Agents do not replace matching, rules or audit; they use them. P
Brenus Pharma Announces FDA Acceptance of IND Application for STC-1010 (BreAK-CRC001) in MSS Metastatic Colorectal Cancer (mCRC)27.5.2026 08:49:00 CEST | Press release
STC-1010 is a first-in-class allogeneic in vivo immunotherapy for which the FDA has authorized clinical evaluation in the U.S. under the BreAK-CRC001 study. This strategic milestone enables the company to execute a global clinical strategy following European regulatory approvals (ANSM, AFMPS), first patients dosed with preliminary results and good tolerability observed in early Phase Ia. First data are expected to be presented during ESMO annual congress 2026. Brenus Pharma, a clinical stage biotechnology company developing novel in vivo immunotherapies for solid tumors, announced that the U.S. Food and Drug Administration (FDA) has accept the company's Investigational New Drug (IND) application for its first drug candidate, STC-1010, in microsatellite stable (MSS) metastatic colorectal cancer (mCRC). STC-1010 is designed to address a critical unmet need worldwide. Approximately 95% of mCRC patients have MSS tumors, which demonstrate minimal response to standard immunotherapies. The FD
Tide Crosses 2 Million Members Worldwide - Big Step Forward in Mission to Support and Grow Small Businesses27.5.2026 08:00:00 CEST | Press release
Continuing to grow in the UK and internationally, with India seeing especially strong member growth in the last 12 months In the UK, Tide has 15% market share and has helped small businesses access over £1.75bn in credit Rapid roll out of products; from admin, accounting and tax tools; subscription options; payment solutions; government registrations; bill payments and credit Tide, the UK’s leading business management platform, today announces it has crossed 2 million members globally, with India in particular seeing strong growth. More than 1.1 million small businesses joined Tide in India since the company launched there in December 2022. This makes India Tide’s fastest-growing market by member acquisition. The UK is Tide’s home market, with 900,000 SMEs, 15% market share, and the majority of the company’s revenue. Tide’s steadily expanding its presence in Europe, with Germany and France, where the platform is gaining strong traction, thanks to millions of small businesses turning to
Alfasigma presents first data on filgotinib from the Phase 3 OLINGUITO trial in axial spondyloarthritis at EULAR 202627.5.2026 08:00:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific and investor media only.In the OLINGUITO Phase 3 study in radiographic (r) and non-radiographic (nr) axial spondyloarthritis (axSpA) a significantly greater proportion of patients achieved the prespecified primary endpoint of ASAS40 with filgotinib compared with placebo at week 16.The improvements in signs and symptoms of axSpA with filgotinib, an oral, once-daily JAK1 preferential inhibitor, were observed as early as week 1 and maintained over 52 weeks of treatment.In the r-axSpA and nr-axSpA filgotinib groups, of those achieving a response in the prespecified primary endpoint of ASAS40 at week 16, 84.6% and 78.0% maintained their responses to week 52, respectively.In OLINGUITO no new safety signals were observedfor filgotinib over 52 weeks, and the safety profile was consistent with the known overall safety profile.Primary results from the Phase 3 OLINGUITO tria
Royal London Asset Management Expands Relationship with SS&C to Service New Australian Funds27.5.2026 00:00:00 CEST | Press release
SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that Royal London Asset Management, a leading U.K. fund management company, has extended its relationship with SS&C. SS&C Global Investor & Distribution Solutions will provide fund administration and unit registry services for its new range of Australian active funds, including: Royal London Global Equity Diversified Fund Royal London Global Equity Enhanced Fund Royal London Global Equity Select Fund Royal London Short Duration Global High Yield Bond Fund RLAM is part of Royal London, the U.K.’s largest mutual life, pensions and investment company. SS&C services approximately £72bn in assets under management across its U.K. fund range. Equity Trustees will serve as the Responsible Entity for RLAM’s new funds, which have launched with around AUD $1 billion in AUM. The unit trusts are structured as feeder funds, providing investors with indirect exposure to RLAM’s range of Dublin-domiciled Undertakings for Collective Investm
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom